SCHEMBL1936595

SCHEMBL1936595

O=C(O)c1c(-c2ccc(F)cc2)nc2c(Br)cccn12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
AKT1 P31749 3/20 0.41
AKT2 P31751 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
PTGDR2 Q9Y5Y4 4/20 0.40
GPBAR1 Q8TDU6 1/20 0.39
MAPT P10636 1/20 0.38
ALOX5 P09917 1/20 0.37
BCL2L1 Q07817 1/20 0.36
BAD Q92934 1/20 0.36
GRIA1 P42261 2/20 0.35
PTGER1 P34995 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7893129 0.80 AKT1 (0.41) AKT1AKT2ALDH1A1KDM4EHPGD
SCHEMBL13035382 0.79 TP53 (0.43) MEN1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14705971 0.78 ALDH1A1 (0.61) CYP1A2CYP2C9CYP2C19KMT2AALDH1A1
SCHEMBL12306384 0.77 AKT1 (0.41) MEN1CYP1A2CYP2C19KMT2AAKT1
SCHEMBL7896304 0.77 ALDH1A1 (0.63) CYP1A2CYP3A4CYP2C9CYP2C19KMT2A
SCHEMBL7894902 0.77 AKT1 (0.40) CYP1A2CYP2C19AKT1AKT2ALDH1A1
SCHEMBL16678539 0.76 GPBAR1 (0.62) CYP1A2AKT1AKT2ALDH1A1KDM4E
SCHEMBL7893227 0.74 AKT1 (0.39) CYP1A2CYP2C19AKT1AKT2ALDH1A1
SCHEMBL7894246 0.74 ALOX5 (0.40) MEN1CYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL5740019 0.74 ALDH1A1 (0.50) MEN1CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545050-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-01-16 EP disclosed
WO-2011112186-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 WO disclosed
EP-2331502-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed